Lantheus Holdings, Inc.
HealthcareNASDAQ:LNTH · NASDAQ Global Market
+$0.20 today
Vol 0.69M · Avg 0.94M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
21.4%
avg 61.4%
ROIC
12.2%
avg 12.3%
ROA
10.5%
avg 8.4%
Analysis
ROE is currently the strongest return metric at 21.4% versus its period average of 61.4%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ludger Dinkelborg | Head of Research & Development | $13.66M | — | 63 | $35,731.00 | 0.05% |
Robert J. Marshall Jr. | Chief Financial Officer & Treasurer | $991,665.00 | — | 59 | $123,974.00 | 0.19% |
Jean-Claude Provost | Chief Science Officer | $894,790.00 | — | 63 | $38,841.00 | 0.06% |
Thomas Reiner | Chief Science Officer | $894,790.00 | — | — | — | — |
Daniel Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary | $763,085.00 | — | 49 | $117,465.00 | 0.18% |
Amanda Morgan | Chief Commercial Officer | $677,449.00 | — | 47 | $64,748.00 | 0.10% |
Mary Anne Heino | Interim CEO & Executive Chairperson | $673,968.00 | — | 66 | $365,040.00 | 0.56% |
Dorothy Barr | Senior Vice President of Manufacturing & Technical Operations | — | — | — | — | — |
Mark Richard Kinarney | Vice President of Investor Relations | — | — | — | — | — |
Neil Holland | Vice President of Business Insights & Operations | — | — | — | — | — |
Kimberly Brown | Chief Accounting Officer | — | — | 35 | $13,859.00 | 0.02% |
Lee Anne Howe | Chief Information Officer | — | — | — | $365,040.00 | 0.56% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
6
$383.06M
Net Sentiment
$383.06M
Net selling
Most Active
FARALLON PARTNERS L L C/CA
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 6 sells worth $383.06M over the last 12 months. That adds up to net selling of $383.06M. FARALLON PARTNERS L L C/CA was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +0.6% | +14.3% (15yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | +24.9% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Revenue at +0.6% over three years. Forward estimates point to EBIT at +24.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.17B
Hinge Health, Inc.
NYSE:HNGE
$5.06B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.80B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.91B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.90B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Who manages LNTH?
Lantheus Holdings, Inc. (LNTH) lists 12 active executives. The top listed executive is Dorothy Barr, Senior Vice President of Manufacturing & Technical Operations.
Are LNTH insiders buying or selling?
Recent insider activity shows net selling of $399.66M.
Explore More
Continue the stock analysis
Jump to another research area for this company.